Attention Deficit Hyperactivity Disorder (ADHD) Market by Technology, Products & Services Application, and End User - Opportunity Analysis and Industry Forecast 2018-2022
Attention Deficit Hyperactivity Disorder (ADHD) Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts.
(EMAILWIRE.COM, August 08, 2018 ) Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis and Outlook (2018-2022) Report provides an extensive research on the fast-evolving Attention Deficit Hyperactivity Disorder (ADHD) Market. It also gives competitive landscape of the leading companies with regional and global analysis of the market till 2022.
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period of time and varies according to the type of causing factor and according to the age group of the person.
Get Sample PDF of the Report @ http://www.orbisresearch.com/contacts/request-sample/2274236?utm_source=sru
The report profiles the key players of the market including –
• Shire Plc
• Johnson and Johnson
• Eli Lilly & Company
• Novartis International AG.
The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or addiction, low-stress tolerance level, mood swings and many more. Further, on the basis of symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient mental and behavior condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies and EEG biofeedback therapies, physicians could reduce the disorder symptoms and its effects on the individual health.
The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with –
Increasing Pharmaceutical R&D Spending, Growing Healthcare Expenditure, Accelerating Economic Growth, Unmet Treatment Needs and Mounting Occurrence of ADHD
Key trends and developments of this market includes –
Progressing Drugs under Pipeline, High Demand for Dual Therapy and Rising Preference for EEG Biofeedback Therapy.
However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.
Request to Enquire before buying the Report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2274236?utm_source=sru
Table of Content:
ADHD Overview
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Classification
1.5 Diagnosis
1.6 Treatment
2. Global ADHD Market
2.1 Global ADHD Market Value Forecast
2.2 Global ADHD Market Value by Region
2.3 Global ADHD Patient Population Forecast
3. Regional ADHD Market
3.1 The U.S.
3.1.1 The U.S. ADHD Market Value
3.1.2 The U.S. ADHD Market Value Forecast
3.1.3 The U.S. ADHD Market Revenue by Drugs
3.1.4 The U.S. Vyvanse Drug Revenue Forecast
3.1.5 The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast
3.1.6 The U.S. Adderall XR Drug Revenue Forecast
3.1.7 The U.S. ADHD Drugs Revenue by Categories
3.1.8 The U.S. ADHD Adult Patient Population Forecast
3.1.9 The U.S. ADHD Total Prescriptions
3.1.10 The U.S. ADHD Total Prescriptions Forecast
3.1.11 The U.S. ADHD Total Prescriptions by Drugs
3.1.12 The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast
3.1.13 The U.S. Vyvanse Total Prescriptions Forecast
3.1.14 The U.S. Concerta Total Prescriptions Forecast
3.2 Europe
3.2.1 Europe ADHD Market Value Forecast
3.2.2 Europe ADHD Patient Population Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Pharmaceutical R&D Spending
4.1.2 Growing Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Unmet Treatment Needs
4.1.5 Mounting Occurrence of ADHD
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Dual Therapy
4.2.3 Rising Preference for EEG Biofeedback Therapy
4.3 Challenges
4.3.1 Medical Complications of Existing Drug Therapies
4.3.2 High Domination of Generic Pharmaceutical Market
4.3.3 Strict Government Protocols
5. Competitive Landscape
5.1 Global ADHD Market
5.1.1 Key Players – Revenues Comparison
5.1.2 Key Players - Market Cap Comparison
5.1.3 Key Players – ADHD Prescription Cost Comparison
6. Company Profiles
6.1 Shire Plc
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson and Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis International AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period of time and varies according to the type of causing factor and according to the age group of the person.
Get Sample PDF of the Report @ http://www.orbisresearch.com/contacts/request-sample/2274236?utm_source=sru
The report profiles the key players of the market including –
• Shire Plc
• Johnson and Johnson
• Eli Lilly & Company
• Novartis International AG.
The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or addiction, low-stress tolerance level, mood swings and many more. Further, on the basis of symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient mental and behavior condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies and EEG biofeedback therapies, physicians could reduce the disorder symptoms and its effects on the individual health.
The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with –
Increasing Pharmaceutical R&D Spending, Growing Healthcare Expenditure, Accelerating Economic Growth, Unmet Treatment Needs and Mounting Occurrence of ADHD
Key trends and developments of this market includes –
Progressing Drugs under Pipeline, High Demand for Dual Therapy and Rising Preference for EEG Biofeedback Therapy.
However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.
Request to Enquire before buying the Report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2274236?utm_source=sru
Table of Content:
ADHD Overview
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Classification
1.5 Diagnosis
1.6 Treatment
2. Global ADHD Market
2.1 Global ADHD Market Value Forecast
2.2 Global ADHD Market Value by Region
2.3 Global ADHD Patient Population Forecast
3. Regional ADHD Market
3.1 The U.S.
3.1.1 The U.S. ADHD Market Value
3.1.2 The U.S. ADHD Market Value Forecast
3.1.3 The U.S. ADHD Market Revenue by Drugs
3.1.4 The U.S. Vyvanse Drug Revenue Forecast
3.1.5 The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast
3.1.6 The U.S. Adderall XR Drug Revenue Forecast
3.1.7 The U.S. ADHD Drugs Revenue by Categories
3.1.8 The U.S. ADHD Adult Patient Population Forecast
3.1.9 The U.S. ADHD Total Prescriptions
3.1.10 The U.S. ADHD Total Prescriptions Forecast
3.1.11 The U.S. ADHD Total Prescriptions by Drugs
3.1.12 The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast
3.1.13 The U.S. Vyvanse Total Prescriptions Forecast
3.1.14 The U.S. Concerta Total Prescriptions Forecast
3.2 Europe
3.2.1 Europe ADHD Market Value Forecast
3.2.2 Europe ADHD Patient Population Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Pharmaceutical R&D Spending
4.1.2 Growing Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Unmet Treatment Needs
4.1.5 Mounting Occurrence of ADHD
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Dual Therapy
4.2.3 Rising Preference for EEG Biofeedback Therapy
4.3 Challenges
4.3.1 Medical Complications of Existing Drug Therapies
4.3.2 High Domination of Generic Pharmaceutical Market
4.3.3 Strict Government Protocols
5. Competitive Landscape
5.1 Global ADHD Market
5.1.1 Key Players – Revenues Comparison
5.1.2 Key Players - Market Cap Comparison
5.1.3 Key Players – ADHD Prescription Cost Comparison
6. Company Profiles
6.1 Shire Plc
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson and Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis International AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results